Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS)
- PMID: 14598868
- DOI: 10.1515/CCLM.2003.182
Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS)
Abstract
Haemoglobin A1c (HbA1c) is the pre-eminent factor for quantifying the risk of complications in patients with diabetes and for monitoring glycaemia. Intervention to lower blood glucose in the two landmark clinical trials, the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT), led to a reduction in the microvascular complications of diabetes. Glycaemic status could be compared in the UKPDS and DCCT as the Bio-Rad Diamat HPLC analyser, as used in the DCCT, was introduced in 1989 for measurement of HbA1c in the UKPDS, after liaison with the DCCT. Results from other methods used for measurement of glycated haemoglobin during the UKPDS were aligned to this method. The Bio-Rad Diamat analyser in the central laboratory for the UKPDS, reference range 4.5-6.2% HbA1c, was certified as comparable to the DCCT by the National Glycohemoglobin Standardization Program in 1998. A median difference in HbA1c of 0.9% was maintained over 10 years between the intensively and conventionally treated groups in the UKPDS (7.0% vs. 7.9% HbA1c) despite HbA1c increasing over time. Clinical care was transferred to general practitioners after the end of the main glucose control study for post-study monitoring. Over the first 3 years of post-study monitoring, HbA1c rose slightly in the previously intensively treated group with no appreciable increase in the conventional group, due to intensification of therapy. At near-normal HbA1c, < 6%, the updated mean value chosen to reflect glycaemic exposure throughout the UKPDS, the incidence of myocardial infarction was 2-3 times that of microvascular disease, with similar incidences for both complications at >10% updated mean HbA1c. Relationships between the risk of complications of type 2 diabetes and updated mean HbA1c had no observable thresholds. The UKPDS risk engine derived from the UKPDS database calculates coronary heart disease risk using HbA1c as a continuous variable and could now replace the Framingham equations for patients with type 2 diabetes.
Similar articles
-
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).Lancet Diabetes Endocrinol. 2020 Mar;8(3):206-215. doi: 10.1016/S2213-8587(20)30003-6. Epub 2020 Feb 4. Lancet Diabetes Endocrinol. 2020. PMID: 32032540 Clinical Trial.
-
The long and winding road to optimal HbA1c measurement.Clin Chim Acta. 2013 Mar 15;418:63-71. doi: 10.1016/j.cca.2012.12.026. Epub 2013 Jan 11. Clin Chim Acta. 2013. PMID: 23318564 Free PMC article. Review.
-
Glycated hemoglobin standardization--National Glycohemoglobin Standardization Program (NGSP) perspective.Clin Chem Lab Med. 2003 Sep;41(9):1191-8. doi: 10.1515/CCLM.2003.183. Clin Chem Lab Med. 2003. PMID: 14598869 Review.
-
Are European standard deviation targets for haemoglobin A1c too strict?Diabet Med. 1998 Nov;15(11):920-3. doi: 10.1002/(SICI)1096-9136(1998110)15:11<920::AID-DIA700>3.0.CO;2-P. Diabet Med. 1998. PMID: 9827845
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet. 1998 Sep 12;352(9131):837-53. Lancet. 1998. PMID: 9742976 Clinical Trial.
Cited by
-
Effectiveness of structured exercise program on insulin resistance and quality of life in type 2 diabetes mellitus-A randomized controlled trial.PLoS One. 2024 May 21;19(5):e0302831. doi: 10.1371/journal.pone.0302831. eCollection 2024. PLoS One. 2024. PMID: 38771888 Free PMC article. Clinical Trial.
-
The Quality of Preoperative Glycemic Control Predicts Insulin Sensitivity During Major Upper Abdominal Surgery: A Case-Control Study.Ann Surg Open. 2023 Jan 12;4(1):e234. doi: 10.1097/AS9.0000000000000234. eCollection 2023 Mar. Ann Surg Open. 2023. PMID: 37600876 Free PMC article.
-
Case Report: Abnormally Low Glycosylated Hemoglobin A1c Caused by Clinically Silent Rare β-Thalassemia in a Tujia Chinese Woman.Front Endocrinol (Lausanne). 2022 May 4;13:878680. doi: 10.3389/fendo.2022.878680. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600576 Free PMC article.
-
Possible Modifying Effect of Hemoglobin A1c on Genetic Susceptibility to Severe Diabetic Retinopathy in Patients With Type 2 Diabetes.Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):7. doi: 10.1167/iovs.61.10.7. Invest Ophthalmol Vis Sci. 2020. PMID: 32756921 Free PMC article.
-
Diabetes Detection and Communication among Patients Admitted through the Emergency Department of a Public Hospital.Int J Environ Res Public Health. 2020 Feb 4;17(3):980. doi: 10.3390/ijerph17030980. Int J Environ Res Public Health. 2020. PMID: 32033242 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical